# Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers

> **NCT05191862** · PHASE1 · TERMINATED · sponsor: **Genovate Biotechnology Co., Ltd.,** · enrollment: 19 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** Cilostazol 100 mg
- **DRUG:** PMR 135 mg

## Key facts

- **NCT ID:** NCT05191862
- **Lead sponsor:** Genovate Biotechnology Co., Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-23
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-07
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Randomization Error
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191862, "Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05191862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*